Your session is about to expire
← Back to Search
ACC Inhibitor
PF-06865571 for Non-alcoholic Fatty Liver Disease
Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to at least 28 days after the last administration of the study intervention or until study completion or withdrawal, whichever was longer (maximum of approximately 24 weeks).
Awards & highlights
Study Summary
This trial will study whether a new drug can help reduce fat in the liver and improve triglyceride levels when taken with another drug. The trial has two parts, and data from the first part will be used to decide whether to do the second part.
Eligible Conditions
- Non-alcoholic Fatty Liver Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to at least 28 days after the last administration of the study intervention or until study completion or withdrawal, whichever was longer (maximum of approximately 24 weeks).
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to at least 28 days after the last administration of the study intervention or until study completion or withdrawal, whichever was longer (maximum of approximately 24 weeks).
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent Change From Baseline (CFB) in Percent (%) Liver Fat as Assessed Via Magnetic Resonance Imaging Using Proton Density Fat Fraction Acquisition (MRI-PDFF) at Week 6
Secondary outcome measures
Number of Participants With Abnormalities in Laboratory Parameters of Special Interest Meeting Pre-Defined Criteria
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
Number of Participants With Post-Baseline Electrocardiogram (ECG) Data Meeting Pre-Defined Criteria
+4 moreSide effects data
From 2022 Phase 2 trial • 75 Patients • NCT0439953811%
Diarrhoea
6%
Thrombocytopenia
6%
Cytokeratin 18 increased
6%
Hypertriglyceridaemia
6%
Alanine aminotransferase increased
6%
Vomiting
6%
Type 2 diabetes mellitus
100%
80%
60%
40%
20%
0%
Study treatment Arm
PF-06865571 300 mg QD + PF-05221304 20 mg QD
Placebo
PF-06865571 25 mg BID + PF-05221304 10 mg BID
PF-06865571 100 mg BID + PF-05221304 10 mg BID
PF-06865571 300 mg BID + PF-05221304 10 mg BID
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: DGAT2i (300 mg QD) + ACCi (20 mg QD)Experimental Treatment2 Interventions
Participants will receive medication for 6 weeks
Group II: DGAT2i (300 mg BID) + ACCi (10 mg BID)Experimental Treatment2 Interventions
Participants will receive medication for 6 weeks
Group III: DGAT2i (25 mg BID) + ACCi (10 mg BID)Experimental Treatment2 Interventions
Participants will receive medication for 6 weeks
Group IV: DGAT2i (100 mg BID) + ACCi (10 mg BID)Experimental Treatment2 Interventions
Participants will receive medication for 6 weeks
Group V: PlaceboPlacebo Group1 Intervention
Participants will receive medication for 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-05221304
2016
Completed Phase 2
~780
PF-06865571
2018
Completed Phase 2
~480
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,570 Previous Clinical Trials
10,910,403 Total Patients Enrolled
16 Trials studying Non-alcoholic Fatty Liver Disease
2,245 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,475 Previous Clinical Trials
8,091,517 Total Patients Enrolled
9 Trials studying Non-alcoholic Fatty Liver Disease
964 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Ohio
How old are they?
18 - 65
What site did they apply to?
Sterling Research Group - Springdale
What portion of applicants met pre-screening criteria?
Met criteria
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Email
Most responsive sites:
- Sterling Research Group - Springdale: < 48 hours
Share this study with friends
Copy Link
Messenger